Insulin Icodec - the once a week long acting insulin from Novo Nordisk | Diabettech - Diabetes and Technology
Novo Nordisk to file for regulatory approval of once-weekly insulin icodec next year
Novo Nordisk Once-Weekly Insulin Comparable to Daily Injections - Type 2 Nation
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
The promising future of insulin therapy in diabetes mellitus | American Journal of Physiology-Endocrinology and Metabolism
Novo Nordisk Once-weekly Insulin Icodec Shows Comparable Efficacy To Once-daily Insulin Glargine U100 in Phase 2 trial
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment | NEJM
Once-weekly insulin efficacy similar to daily therapy in type 2 diabetes
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Novo Scores Phase III Insulin Icodec Win, Potentially Strengthening Market Position | BioSpace
Novo Nordisk reaches primary endpoint in phase III of once-weekly insulin — MedWatch
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Novo Nordisk bolstered by another late-stage trial of once weekly insulin icodec (NVO) | Seeking Alpha
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Novo Nordisk's insulin icodec beats other insulin therapies in diabetes study | S&P Global Market Intelligence
Novo's Once-Weekly Insulin Treatment Part of a Transforming T2D Space | BioSpace
Novo Nordisk once weekly insulin icodec bests Tresiba in lowering blood sugar (NYSE:NVO) | Seeking Alpha
Novo Nordisk achieve headline results with icodec insulin | pharmaphorum
Novo Nordisk's once-weekly insulin hits goals in phase 3 trials
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
